Meningococcal Infections Completed Phase 2 Trials for Meningococcal polysaccharide vaccine group W-135 (DB13887)

Also known as: Infections, Meningococcal / Meningococcal Infection / Meningococcal disease / Unspecified meningococcal infection / Meningococcal infection, unspecified / Neisseria meningitidis infection NOS

IndicationStatusPhase
DBCOND0032814 (Meningococcal Infections)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03652610A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of AgePrevention
NCT00661557Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated SubjectsPrevention
NCT00356369Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate VaccinePrevention
NCT00427908Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612Prevention
NCT00715910The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/AdultsPrevention
NCT03205358Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy ToddlersPrevention
NCT02199691Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy AdolescentsPrevention